IP Library Granted Patent US 11,957,648
Granted Patent B2
US 11,957,648 · App. 17/380,413 · Granted Apr 16, 2024

Method of initiating or escalating dofetilide dose and formulations therefor

Inventor: John Somberg (Lake Bluff, IL)
Assignee: HYLORIS DEVELOPMENTS S.A.
A61K31/18A61K9/0019A61K9/0053A61K47/02A61K47/10A61K47/12A61K47/18A61K47/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,957,648
App. No.
17/380,413
Granted
Apr 16, 2024
Kind
B2
Abstract

The present invention provides a novel method of initiating or escalating dofetilide dosage with the goal of maximizing patient safety while shortening the time period required for electrocardiographic monitoring from three days to one day.

Claims (23)

1. A dofetilide pharmaceutical composition, comprising:

a. 10-1000 μg/mL Dofetilide;

b. 1-20% by volume 1,3-propanediol; and

c. water;

wherein the composition suitable for intravenous solution.

2. The composition of claim 1 , wherein the concentration of dofetilide is 50 μg/mL.

3. The composition of claim 1 , wherein the concentration of 1,3-propanediol is 5% by volume.

4. A dofetilide pharmaceutical composition, comprising:

a. 10-1000 μg/mL Dofetilide;

b. 0.005-0.015 M HCl;

c. 0.05-0.15 M acetic acid;

d. 0.05-0.15 M sodium acetate; and

e. water;

wherein the composition suitable for intravenous solution.

5. The composition of claim 4 , wherein the concentration of dofetilide is 50 μg/mL.

6. The composition of claim 4 , wherein the concentration of of HCl is 0.01M, acetic acid is 0.09M, and sodium acetate is 0.09M.

7. A dofetilide pharmaceutical composition, comprising:

a. 10-1000 μg/mL Dofetilide;

b. 0.1-5% by volume N,N-Dimethylacetamide; and,

c. 1-50% D-glucose in water;

wherein the composition suitable for intravenous solution.

8. The composition of claim 7 , wherein the concentration of dofetilide is 50 μg/mL.

9. The composition of claim 7 , wherein the concentration of N,N-Dimethylacetamide is 1% by volume and the remainder is 5% D-glucose in water.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2022
From: ACADEMIC PHARMACEUTICALS, INC.
To: HYLORIS DEVELOPMENTS S.A.
Reel/Frame 059974/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2021
From: SOMBERG, JOHN
To: ACADEMIC PHARMACEUTICALS INC
Reel/Frame 058398/0719 →
Continuity (3)
Division 16449796 · Jun 24, 2019
Provisional Application 62689442 · Jun 25, 2018
Related Publication 20210346325A1 · Nov 11, 2021
Cited By (1)
US 12,396,970